Objective:To develop a nomogram model based on the preoperative neutrophil-to-lymphocyte ratio and gamma-glutamyl transpeptidase (GGT) -to-platelet ratio (NLR-GPR) score to predict the prognosis of patients with hepatocellular carcinoma (HCC) undergoing hepatectomy.Methods:Clinical data of 284 patients with HCC who underwent curative resection at Taizhou Hospital of Zhejiang Province between January 2012 and September 2016 were retrospectively analyzed, including 235 males and 49 females, aged 57(51, 65) years. Clinical data, including gender, age, neutrophil count, lymphocyte count, platelet count, GGT, and total bilirubin, were collected. The Cox proportional hazards regression model was employed to assess the relationship between the preoperative NLR-GPR score and patient disease-free survival (DFS) and overall survival (OS). A nomogram was constructed based on the results of the multivariate analysis. Survival curves were generated using the Kaplan-Meier method, and differences between groups were evaluated using the log-rank test. The performance of the model was assessed by the concordance index (C-index).Results:The NLR-GPR score was found to be negatively correlated with both DFS and OS (both P<0.05), where a higher score indicated a poorer prognosis. Multivariate analysis identified the NLR-GPR score as an independent risk factor for both DFS ( HR=1.463, 95% CI: 1.135-1.887, P=0.003) and OS ( HR=1.734, 95% CI: 1.300-2.313, P<0.001). A nomogram was deve-loped based on the variables selected from the multivariate Cox regression analysis, including postoperative pleural effusion, AJCC stage, vascular invasion, and the NLR-GPR score. This nomogram demonstrated good predictive accuracy, with C-indices for DFS and OS of 0.676 and 0.726, respectively. Conclusion:The nomogram model, constructed based on the preoperative NLR-GPR score and relevant clinicopathological factors, can effectively predict the postoperative survival of patients with HCC undergoing hepatectomy.

Objective:To develop a nomogram model based on the preoperative neutrophil-to-lymphocyte ratio and gamma-glutamyl transpeptidase (GGT) -to-platelet ratio (NLR-GPR) score to predict the prognosis of patients with hepatocellular carcinoma (HCC) undergoing hepatectomy.Methods:Clinical data of 284 patients with HCC who underwent curative resection at Taizhou Hospital of Zhejiang Province between January 2012 and September 2016 were retrospectively analyzed, including 235 males and 49 females, aged 57(51, 65) years. Clinical data, including gender, age, neutrophil count, lymphocyte count, platelet count, GGT, and total bilirubin, were collected. The Cox proportional hazards regression model was employed to assess the relationship between the preoperative NLR-GPR score and patient disease-free survival (DFS) and overall survival (OS). A nomogram was constructed based on the results of the multivariate analysis. Survival curves were generated using the Kaplan-Meier method, and differences between groups were evaluated using the log-rank test. The performance of the model was assessed by the concordance index (C-index).Results:The NLR-GPR score was found to be negatively correlated with both DFS and OS (both P<0.05), where a higher score indicated a poorer prognosis. Multivariate analysis identified the NLR-GPR score as an independent risk factor for both DFS ( HR=1.463, 95% CI: 1.135-1.887, P=0.003) and OS ( HR=1.734, 95% CI: 1.300-2.313, P<0.001). A nomogram was deve-loped based on the variables selected from the multivariate Cox regression analysis, including postoperative pleural effusion, AJCC stage, vascular invasion, and the NLR-GPR score. This nomogram demonstrated good predictive accuracy, with C-indices for DFS and OS of 0.676 and 0.726, respectively. Conclusion:The nomogram model, constructed based on the preoperative NLR-GPR score and relevant clinicopathological factors, can effectively predict the postoperative survival of patients with HCC undergoing hepatectomy.

OBJECTIVETo evaluate the efficacy of decitabine (DAC) bridging therapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myelodysplastic syndrome (MDS).

METHODSThe clinical characteristics and curative effect of MDS patients who received allo-HSCT from 2010 July to 2013 December were retrospectively analyzed. Of them, 25 MDS patients who received decitabine bridging allo-HSCT were randomly selected (referred to as the bridging group),while at the same time another 33 MDS patients who did not receive decitabine for allo-HSCT in MDS were also randomly selected as control group. The effect of decitabine bridging allo-HSCT on the patients' survival and occurrence of graft versus host disease (GVHD) was analyzed.

RESULTSWith decitabine bridge therapy, 64.0% patients (16/25) achieved marrow complete remission before allo-HSCT, while the control group was only 15.1% (5/33, P<0.05). Decitabine bridging group of early transplant-related mortality was lower than that of the control group (4.0% vs 18.2%), but the difference was not statistically significant (P=0.106). Up to follow-up deadline, the mortality of decitabine bridging group was 12.0%, while that of the control group was 30.3% (P<0.05). The 2-year OS of decitabine bridging group was 83.0%, while that of the control group was 59.0% (P<0.05). Of the 14 patients in decitabine bridging group with aGVHD, 7 was grade IaGVHD, 3 grade II and 4 grade III. Of the 16 patients in control group with aGVHD, 7 was grade IaGVHD, 8 grade II and 1 grade III.

CONCLUSIONDecitabine bridging therapy followed by allo-HSCT in the treatment of MDS is safe and effective.

Azacitidine ; analogs & derivatives ; Graft vs Host Disease ; Hematopoietic Stem Cell Transplantation ; Humans ; Myelodysplastic Syndromes ; Retrospective Studies ; Transplantation, Homologous